Drugs / Combigan
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | COMBIGAN | — | 2007-10-30 | fda.gov ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT00442312 | May → Nov 2006 | glaucoma | Genovate Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT04296916 | Apr 2020 → Oct 2024 | borderline glaucoma, myopia | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT02718547 | Mar 2017 → Mar 2018 | diabetic retinopathy | Meir Medical Center | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT03235232 Comparator | Feb 2021 → Jul 2023 | ocular hypertension, open-angle glaucoma | EMS | Completed | No outcome recorded |
| Phase 4 | NCT02167035 Comparator | Aug 2014 → Mar 2018 | glaucoma, ocular hypertension | Cornerstone Health Care, PA | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Combigan | “If necessary, latanoprost and timolol will be switched to Xalacom eye drops, timolol and alphagan will be switched to Combigan eye drops, timolol and brinzolamide will be...” NCT04296916 ↗ |
| Route | Topical | “1 drop of Combigan® in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.” NCT03235232 ↗ |